Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 4/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749640 | 1.00 | BTK (0.41) | BTKCSNK1DCKS1BSKP1SKP2 | |
| SCHEMBL4375798 | 0.90 | BTK (0.39) | BTKCSNK1DCKS1BSKP1SKP2 | |
| SCHEMBL1749302 | 0.80 | BTK (0.41) | BTKCKS1BSKP1SKP2MERTK | |
| SCHEMBL1749305 | 0.80 | BTK (0.41) | BTKCKS1BSKP1SKP2MERTK | |
| SCHEMBL1749438 | 0.78 | PIK3CB (0.55) | CSNK1DCKS1BSKP1SKP2 | |
| SCHEMBL1749439 | 0.78 | PIK3CB (0.55) | CSNK1DCKS1BSKP1SKP2 | |
| SCHEMBL4714087 | 0.74 | ALDH1A1 (0.52) | BTKCKS1BSKP1SKP2MERTK | |
| SCHEMBL4714088 | 0.74 | ALDH1A1 (0.52) | BTKCKS1BSKP1SKP2MERTK | |
| SCHEMBL22411335 | 0.73 | ALOX15 (0.47) | JAK2JAK3ALOX15 | |
| SCHEMBL29363185 | 0.73 | ALOX15 (0.47) | JAK2JAK3ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383634-B2 | Methods of treatment using heteroaryl compounds and compositions thereof | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | SIGNAL PHARMACEUTICALS, LLC | 2011-09-15 | — | — | US | disclosed |
| US-7968556-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | JAK2, CHEK2, PHKG1 | BTK 22/4885CSNK1D 585/4885CKS1B 227/4885 |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, SRC | BTK 49/4885CSNK1D 832/4885CKS1B 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.